196 related articles for article (PubMed ID: 31741320)
1. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study.
Colao A; Grasso LFS; Di Cera M; Thompson-Leduc P; Cheng WY; Cheung HC; Duh MS; Neary MP; Pedroncelli AM; Maamari R; Pivonello R
J Endocrinol Invest; 2020 Apr; 43(4):529-538. PubMed ID: 31741320
[TBL] [Abstract][Full Text] [Related]
2. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
3. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
4. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
6. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
7. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
8. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
10. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.
Carosi G; Mangone A; Sala E; Del Sindaco G; Mungari R; Cremaschi A; Ferrante E; Arosio M; Mantovani G
Eur J Endocrinol; 2021 Jul; 185(2):289-297. PubMed ID: 34081617
[TBL] [Abstract][Full Text] [Related]
11. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.
Pollock BE; Jacob JT; Brown PD; Nippoldt TB
J Neurosurg; 2007 May; 106(5):833-8. PubMed ID: 17542527
[TBL] [Abstract][Full Text] [Related]
12. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.
Gutt B; Hatzack C; Morrison K; Pöllinger B; Schopohl J
Eur J Endocrinol; 2001 Feb; 144(2):109-16. PubMed ID: 11182746
[TBL] [Abstract][Full Text] [Related]
13. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
14. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
15. Serum phosphate: Does it more closely reflect the true state of acromegaly?
Xie T; Tian P; Wu S; Zhang X; Liu T; Gu Y; Sun C; Hu F
J Clin Neurosci; 2020 Jan; 71():26-31. PubMed ID: 31859176
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
Niculescu D; Purice M; Coculescu M
Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
[TBL] [Abstract][Full Text] [Related]
18. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
[TBL] [Abstract][Full Text] [Related]
19. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
20. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]